Literature DB >> 20026298

Overcoming rapid inactivation of lung surfactant: analogies between competitive adsorption and colloid stability.

Joseph A Zasadzinski1, Patrick C Stenger, Ian Shieh, Prajna Dhar.   

Abstract

Lung surfn class="Chemical">actant (LS) is a mixture of n>n class="Chemical">lipids and proteins that line the alveolar air-liquid interface, lowering the interfacial tension to levels that make breathing possible. In acute respiratory distress syndrome (ARDS), inactivation of LS is believed to play an important role in the development and severity of the disease. This review examines the competitive adsorption of LS and surface-active contaminants, such as serum proteins, present in the alveolar fluids of ARDS patients, and how this competitive adsorption can cause normal amounts of otherwise normal LS to be ineffective in lowering the interfacial tension. LS and serum proteins compete for the air-water interface when both are present in solution either in the alveolar fluids or in a Langmuir trough. Equilibrium favors LS as it has the lower equilibrium surface pressure, but the smaller proteins are kinetically favored over multi-micron LS bilayer aggregates by faster diffusion. If albumin reaches the interface, it creates an energy barrier to subsequent LS adsorption that slows or prevents the adsorption of the necessary amounts of LS required to lower surface tension. This process can be understood in terms of classic colloid stability theory in which an energy barrier to diffusion stabilizes colloidal suspensions against aggregation. This analogy provides qualitative and quantitative predictions regarding the origin of surfactant inactivation. An important corollary is that any additive that promotes colloid coagulation, such as increased electrolyte concentration, multivalent ions, hydrophilic non-adsorbing polymers such as PEG, dextran, etc. added to LS, or polyelectrolytes such as chitosan, also promotes LS adsorption in the presence of serum proteins and helps reverse surfactant inactivation. The theory provides quantitative tools to determine the optimal concentration of these additives and suggests that multiple additives may have a synergistic effect. A variety of physical and chemical techniques including isotherms, fluorescence microscopy, electron microscopy and X-ray diffraction show that LS adsorption is enhanced by this mechanism without substantially altering the structure or properties of the LS monolayer. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Debye length; albumin; charge reversal; chitosan; depletion attraction; inhibition; polyethylene glycol

Mesh:

Substances:

Year:  2009        PMID: 20026298      PMCID: PMC2834873          DOI: 10.1016/j.bbamem.2009.12.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  149 in total

1.  Pulmonary edema and permeability of alveolar membranes.

Authors:  J A CLEMENTS
Journal:  Arch Environ Health       Date:  1961-03

2.  Steric interactions in a model multimembrane system: A synchrotron x-ray study.

Authors: 
Journal:  Phys Rev Lett       Date:  1986-11-24       Impact factor: 9.161

3.  Biophysical inhibition of synthetic lung surfactants.

Authors:  B A Holm; A R Venkitaraman; G Enhorning; R H Notter
Journal:  Chem Phys Lipids       Date:  1990-02       Impact factor: 3.329

4.  Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: theory.

Authors:  Joseph A Zasadzinski; T F Alig; Coralie Alonso; Jorge Bernardino de la Serna; Jesus Perez-Gil; H William Taeusch
Journal:  Biophys J       Date:  2005-07-08       Impact factor: 4.033

5.  Poly(ethylene glycol) (PEG) enhances dynamic surface activity of a bovine lipid extract surfactant (BLES).

Authors:  James J Lu; Laura M Y Yu; Wendy W Y Cheung; Irene A Goldthorpe; Yi Y Zuo; Zdenka Policova; Peter N Cox; A Wilhelm Neumann
Journal:  Colloids Surf B Biointerfaces       Date:  2005-01-08       Impact factor: 5.268

6.  Multiple mechanisms of lung surfactant inhibition.

Authors:  B A Holm; Z Wang; R H Notter
Journal:  Pediatr Res       Date:  1999-07       Impact factor: 3.756

7.  Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome.

Authors:  Roger G Spragg; James F Lewis; Hans-Dieter Walmrath; Jay Johannigman; Geoff Bellingan; Pierre-Francois Laterre; Michael C Witte; Guy A Richards; Gerd Rippin; Frank Rathgeb; Dietrich Häfner; Friedemann J H Taut; Werner Seeger
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

8.  Atomic force microscopy studies of functional and dysfunctional pulmonary surfactant films, II: albumin-inhibited pulmonary surfactant films and the effect of SP-A.

Authors:  Yi Y Zuo; Seyed M Tadayyon; Eleonora Keating; Lin Zhao; Ruud A W Veldhuizen; Nils O Petersen; Matthias W Amrein; Fred Possmayer
Journal:  Biophys J       Date:  2008-06-06       Impact factor: 4.033

9.  Zero spontaneous curvature and its effects on lamellar phase morphology and vesicle size distributions.

Authors:  Bret A Coldren; Heidi Warriner; Ryan van Zanten; Joseph A Zasadzinski; Eric B Sirota
Journal:  Langmuir       Date:  2006-03-14       Impact factor: 3.882

10.  Mechanisms of polyelectrolyte enhanced surfactant adsorption at the air-water interface.

Authors:  Patrick C Stenger; Omer A Palazoglu; Joseph A Zasadzinski
Journal:  Biochim Biophys Acta       Date:  2009-01-27
View more
  21 in total

1.  Lipid-protein interactions alter line tensions and domain size distributions in lung surfactant monolayers.

Authors:  Prajnaparamita Dhar; Elizabeth Eck; Jacob N Israelachvili; Dong Woog Lee; Younjin Min; Arun Ramachandran; Alan J Waring; Joseph A Zasadzinski
Journal:  Biophys J       Date:  2012-01-03       Impact factor: 4.033

Review 2.  Endogenous and exogenous cell-based pathways for recovery from acute respiratory distress syndrome.

Authors:  Jeffrey E Gotts; Michael A Matthay
Journal:  Clin Chest Med       Date:  2014-09-24       Impact factor: 2.878

3.  Exposure to polymers reverses inhibition of pulmonary surfactant by serum, meconium, or cholesterol in the captive bubble surfactometer.

Authors:  Elena López-Rodríguez; Olga Lucía Ospina; Mercedes Echaide; H William Taeusch; Jesús Pérez-Gil
Journal:  Biophys J       Date:  2012-10-02       Impact factor: 4.033

4.  Protein assembly at the air-water interface studied by fluorescence microscopy.

Authors:  Zhengzheng Liao; Joshua W Lampe; Portonovo S Ayyaswamy; David M Eckmann; Ivan J Dmochowski
Journal:  Langmuir       Date:  2011-10-03       Impact factor: 3.882

5.  Visualizing the analogy between competitive adsorption and colloid stability to restore lung surfactant function.

Authors:  Ian C Shieh; Alan J Waring; Joseph A Zasadzinski
Journal:  Biophys J       Date:  2012-02-21       Impact factor: 4.033

6.  The unusual symmetric reopening effect induced by pulmonary surfactant.

Authors:  Eiichiro Yamaguchi; Matthew J Giannetti; Matthew J Van Houten; Omid Forouzan; Sergey S Shevkoplyas; Donald P Gaver
Journal:  J Appl Physiol (1985)       Date:  2014-01-23

7.  Inflammation product effects on dilatational mechanics can trigger the Laplace instability and acute respiratory distress syndrome.

Authors:  Sourav Barman; Michael L Davidson; Lynn M Walker; Shelly L Anna; Joseph A Zasadzinski
Journal:  Soft Matter       Date:  2020-07-29       Impact factor: 3.679

8.  The influence of surfactant on the propagation of a semi-infinite bubble through a liquid-filled compliant channel.

Authors:  David Halpern; Donald P Gaver
Journal:  J Fluid Mech       Date:  2012-03-30       Impact factor: 3.627

9.  Effect of cholesterol nanodomains on monolayer morphology and dynamics.

Authors:  Kyuhan Kim; Siyoung Q Choi; Zachary A Zell; Todd M Squires; Joseph A Zasadzinski
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-30       Impact factor: 11.205

Review 10.  Delivery and performance of surfactant replacement therapies to treat pulmonary disorders.

Authors:  Nashwa El-Gendy; Anubhav Kaviratna; Cory Berkland; Prajnaparamita Dhar
Journal:  Ther Deliv       Date:  2013-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.